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Abstract
Drugs that mobilise the immune system against cancer are
dramatically improving care for many people. Dying cancer cells
play an active role in inducing anti-tumour immunity but not
every form of death can elicit an immune response. Moreover,
resistance to apoptosis is a major problem in cancer treatment
and disease control. While the term “immunogenic cell death”
is not fully defined, activation of receptor-interacting serine/
threonine-protein kinase 1 (RIPK1) can induce a type of death
that mobilises the immune system against cancer. However, no
clinical treatment protocols have yet been established that
would harness the immunogenic potential of RIPK1. Here, we
report the first pre-clinical application of an in vivo treatment
protocol for soft-tissue sarcoma that directly engages RIPK1-
mediated immunogenic cell death. We find that RIPK1-mediated
cell death significantly improves local disease control, increases
activation of CD8+ T cells as well as NK cells, and enhances the
survival benefit of immune checkpoint blockade. Our findings
warrant a clinical trial to assess the survival benefit of RIPK1-
induced cell death in patients with advanced disease at limb
extremities.
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Introduction
Dying cells have an important role in the initiation of T-cell-
mediated immunity (Kroemer et al, 2013). The cross-presentation of
antigens derived from dying cells enables dendritic cells to present
exogenous tissue-restricted or tumour-restricted proteins. Cell death
mechanisms that are indicative of danger to the organism (e.g.
inflammatory cell death triggered by pathogens) are potent inducers
of immune responses (Ho et al, 2018). Cancer cells that die in this
manner release inducible and constitutive DAMPs (damage-asso-
ciated molecular patterns), which are direct upstream drivers of
anti-tumour immunity (Yatim et al, 2017).
While the term “immunogenic cell death” is not yet fully defined,
it is clear that activation of receptor-interacting serine/threonine-
protein kinase 1 (RIPK1), and formation of ripoptosome complexes,
can induce a type of death that maximally drives antigen cross-
priming of CD8+ T cells (Yatim et al, 2015; Aaes et al, 2016). Mech-
anistically, this is because the ripoptosome can trigger cell death as
well as the release of chemokines and cytokines from dying cells
that attract and stimulate immune cells (Wu et al, 2007; Yatim et al,
2015, 2017). Importantly, TNF-mediated cell death can also contri-
bute to immune surveillance by cytotoxic lymphocytes (Kearney
et al, 2018; Vredevoogd et al, 2019). Accordingly, in some cases
tumour immune evasion can arise through loss of TNF (tumour
necrosis factor-a) sensitivity, independently of perforin-mediated
killing. Hence, re-sensitising cancer cells to TNF-mediated bystander
killing might be a potent mechanism to kill antigen-negative tumour
cells (Vredevoogd et al, 2019).
Activation of RIPK1 and RIPK1-mediated cell death is best stud-
ied in the context of TNF signalling. RIPK1 is a key node in the TNF
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signal transduction pathway, actively controlling the balance
between gene activation and cell death induction in the form of
apoptosis and necroptosis. The decision as to whether RIPK1
unleashes pro-survival or pro-death signals depends on multiple
control points (Annibaldi & Meier, 2018). In healthy cells, TNFR1
activation results in rapid post-translational modification of RIPK1
at the receptor complex, which actively suppresses the cytotoxic
potential of RIPK1. While the E3-Ub ligases cIAP1, cIAP2, MIB2 and
LUBAC conjugate inhibitory ubiquitin (Ub) chains to RIPK1
(Feltham & Silke, 2017; Annibaldi & Meier, 2018; Feltham et al,
2018), multiple kinases (e.g. IKK, MK2 and TBK1) inactivate RIPK1
via direct phosphorylation (Dondelinger et al, 2015, 2018; Jaco
et al, 2017; Lafont et al, 2018). Together, this limits the ability of
RIPK1 to form a death-inducing platform (Bertrand & Vandenabeele,
2011; Feoktistova et al, 2011; Tenev et al, 2011).
Inhibitor of APoptosis (IAP) protein family members are
frequently overexpressed in cancer and contribute to tumour cell
survival, chemo-resistance, disease progression and poor prognosis
(LaCasse et al, 2008). Although best known for their ability to regu-
late caspases, IAPs also influence TNF signalling via modulation of
RIPK1 and activation of NF-kB (Gyrd-Hansen & Meier, 2010). Not
surprisingly, therefore, IAPs are considered as promising targets for
the design of therapeutic strategies (Fulda, 2017). Pharmacological
inhibition of cIAP1 and cIAP2 abrogates both ubiquitylation of
RIPK1 and Ub-dependent activation of kinases, which in turn phos-
phorylate and inhibit RIPK1. Inhibiting cIAPs, therefore, unleashes
the pro-death potential of RIPK1. Pharmacological inhibitors of
cIAPs, frequently referred to as SMAC mimetics (SM), act by
promoting the degradation of cIAP1 and cIAP2 (Vince et al, 2007;
Bai et al, 2014; Fulda, 2015). As these cIAPs are guardians of RIPK1,
this renders cells acutely sensitive to RIPK1-mediated cell death. SM
promote IAP degradation by mimicking the intracellular cIAP antag-
onist SMAC/Diablo (Verhagen et al, 2000). Several SM are being
evaluated in early clinical trials (Cong et al, 2019). For example, the
monovalent SM LCL161 from Novartis completed phase II trials on
triple-negative breast cancer in combination with paclitaxel
(NCT01617668), and on relapsed or refractory multiple myeloma
(NCT01955434). The pathologic complete response (pCR) rate after
12 weeks of therapy was 24.9%, compared to 23.4% observed for
paclitaxel alone, in patients with positive gene expression signature.
Currently, there are at least four phase I or II trials recruiting
patients with other indications to test LCL161 in combination with
other drugs (NCT02098161, NCT02649673, NCT03111992 and
NCT02890069). The bivalent SM Birinapant has been advanced into
several phase I or II trials as a single agent (NCT00993239,
NCT01681368, NCT01486784 and NCT01681368) or in combination
with gemcitabine (NCT01573780), 5-azacitidine (NCT02147873,
NCT01828346) or other standard chemotherapeutics such as
irinotecan or docetaxel (NCT01188499), carboplatin (NCT02
756130), conatumumab (NCT01940172) and pembrolizumab
(NCT02587962). Even though SM are well tolerated, they have
limited single agent efficacy in most cancers due to the low concen-
tration of TNF in the tumour microenvironment that would drive
RIPK1-dependent cell death in the absence of cIAPs (Fulda, 2015).
Although TNF can drive RIPK1-induced cell death, the premise
to harness the cytotoxic properties of TNF as an anticancer therapy
is limited by the severe toxicity that results upon its systemic admin-
istration (Duprez et al, 2011; Zelic et al, 2018). However, such
treatment-limiting toxicities can be avoided by the locoregional
administration of TNF via isolated limb perfusion (ILP), a specia-
lised surgical treatment of extremity malignancies (Eggermont et al,
2003). Indeed, application of TNF, most commonly in combination
with melphalan (Mel), represents the current standard-of-care
(SOC) treatment for targeting cancers in the extremities that are
unsuitable for surgical resection, such as extremity soft-tissue sarco-
mas (ESTS, which represent 40% of soft-tissue sarcomas), squa-
mous cell carcinoma (SCC), Merkel cell carcinoma (MCC), in-transit
melanoma and fibromatosis (Smith & Hayes, 2016). Sarcomas
account for > 20% of all paediatric solid malignant cancers and
< 1% of all adult solid malignant cancers. Soft-tissue sarcomas are
the most frequent, with fibrosarcomas accounting for roughly 7% of
all sarcomas. During the procedure of isolated limb perfusion, TNF
is used for its vasodilating properties, allowing enhanced uptake of
Mel by the tumour (Deroose et al, 2011b). However, at present, the
cytotoxic properties of the cytokine are not being exploited by the
TNF/Mel standard-of-care ILP regimen. Clearly, improvements to
the ILP standard-of-care treatment regimen are urgently needed as
the duration of response is limited in the absence of any further
intervention, with the majority of patients developing locally
progressive disease within 12 months (Smith et al, 2015).
To evaluate the possibility of harnessing RIPK1’s cytotoxic poten-
tial during ILP, we combined the current standard-of-care treatment
regimen (ILP-TNF/Mel) with pharmacological inhibitors of IAPs
(SM) and evaluated its efficacy in an immune-competent rat model
of extremity sarcoma (ESTS). Our data demonstrate that the combi-
nation of TNF/Mel with SM mediates RIPK1-dependent cell death,
which significantly improves local disease control. Mechanistically,
RIPK1-mediated cell death increases activation of infiltrating CD8+
T cells and NK cells and enhances the survival benefit of immune
checkpoint blockage. Our work warrants clinical evaluation in
patients with ESTS.
Results
Combination therapy with SM results in Ripk1-assisted cell death
following standard-of-care TNF/Mel treatment
Treatment with TNF and melphalan via isolated limb perfusion
(ILP) represents a standard-of-care treatment protocol for advanced
extremity malignancies unsuitable for surgical resection (Lienard
et al, 1992; Eggermont et al, 2003). Although 60% of patients have
a significant response to ILP-TNF/Mel (Smith & Hayes, 2016), the
duration of response is limited with median progression-free
survival limited to 12 months (Smith et al, 2015). Therefore, novel
agents or treatment combinations are urgently needed to improve
outcome.
To evaluate the possibility of harnessing RIPK1’s cytotoxic and
immunogenic potential during ILP-based and TNF-mediated treat-
ments in combination with SM, we employed a syngeneic, immune-
competent rat model of ILP-TNF/Mel using the syngeneic BN175
sarcoma cell line in Brown Norway rats (Pencavel et al, 2015;
Wilkinson et al, 2016). Due to the complex micro-surgical proce-
dures involved during ILP, in vivo investigation of this technique
requires the use of a rat rather than a mouse model. Importantly,
this rat model closely resembles the clinical scenario seen in many
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patients with advanced limb sarcomas after treatment with standard
ILP-TNF/Mel, where an initial local response is followed by local
disease progression that may occur before the development of meta-
static disease (Pencavel et al, 2015; Wilkinson et al, 2016; Smith
et al, 2019). Prior to in vivo application, we first evaluated the death
pathways that are activated in BN175 cells upon treatment with
various combinations of TNF, Mel and SM in an in vitro setting.
While the standard-of-care treatment TNF/Mel reduced cell
viability of BN175 cells only at later time points (48 h), the addition
of SM to TNF/Mel potently killed these cells at an early time point
(24 h; Fig 1A, left panel). Also, at later time points, TNF/Mel/SM
was more effective in killing BN175 cells than the standard-of-care
treatment. Importantly, TNF/Mel/SM resulted in potent complex-II
formation and caspase activation (Figs 1B–D and EV1A). In
complete contrast, the standard-of-care treatment TNF/Mel did not
drive formation of Ripk1:Caspase-8 (Casp-8) complexes, as judged
by co-immunoprecipitation with an anti-FADD antibody and prox-
imity ligation assay (PLA) with specific antibodies for Ripk1 and
Casp-8 that successfully detect complex-II formation (Orme et al,
2016; Liccardi et al, 2018). Co-treatment with SM caused cell death
that was dependent on the kinase activity of Ripk1 and Casp-8 at
24 h. This is evident as cell death was suppressed by genetic or
pharmacological inhibition of Ripk1 or Casp-8 (Figs 1E, and EV1B
and C). Previous work established that treatment with Mel activates
the intrinsic death pathway (Matsura et al, 2004; Gomez-Bougie
et al, 2005; Park et al, 2013). Accordingly, Mel and TNF/Mel treat-
ment of BN175 resulted in increased caspase activity, which was
rescued by co-treatment with the caspase inhibitor zVAD-fmk
(Fig EV1D). Ectopic expression of BCL2 also suppressed Mel- or
TNF/Mel-induced intrinsic apoptosis in HT1080 cells (Fig EV1E),
corroborating that exposure to Mel triggers mitochondria-dependent
apoptosis. Not surprisingly, therefore, TNF/Mel-induced cell death
was not affected by loss of Ripk1 or Casp-8, indicating that Mel-
mediated cell death does not involve Ripk1-assisted cell death
(Figs 1E, and EV1B and C).
SM sensitises cells from human extremity malignancies to RIPK1-
induced cell death
Next, we tested the sensitivity of a range of cells derived from malig-
nancies that can be treated via ILP-TNF/Mel to TNF-induced and
RIPK1-dependent cell death. Treatment with TNF resulted in the
formation of the TNF receptor signalling complex-I (TNFR-SC, also
referred to as complex-I) in the human fibrosarcoma cell line
HT1080, as evidenced by the recruitment of bona fide TNFR-SC
components such as RIPK1, SHARPIN and TRADD (Fig EV2A)
(Micheau & Tschopp, 2003). Upon concomitant inhibition of IAPs
with SM-164, TNF potently triggered formation of complex-II
(Fig 2A), caspase activation (Fig EV2B) and cell death (Fig 2B) in
the human fibrosarcoma cell line HT1080. Cell death was blocked
by co-treatment with the caspase inhibitor zVAD-FMK (Fig 2B) or
RIPK1, CASP-8 depletion (Fig 2C), indicating that TNF/SM exclu-
sively drives RIPK1-mediated apoptosis in these cells. Virtually iden-
tical results were obtained in A375, MeWo and DO4 melanoma cells
(Figs 2D–I and EV2C–H), extending this observation to other human
malignancies treated with ILP-TNF/Mel regimen. While most cancer
cells are resistant to treatment with SM alone (Fig 2C, E, F and G),
some cancer cells, such as the sarcoma cell line SW872, are
sensitive to single agent SM treatment (Figs 2I, and EV2C and D).
Importantly, the sensitivity of such cells can be further enhanced by
co-treatment with TNF (Fig 2I).
Extremity malignancies not only comprise of fibrosarcomas and
melanomas but also of epithelioid sarcomas, synovial sarcoma and
cutaneous squamous cell carcinoma (cSCC) (Smith & Hayes, 2016).
Importantly, we found that cells from such malignancies are sensi-
tive to TNF/SM treatment, which is caspase-dependent (Figs 2J and
K, and EV2J and K). Furthermore, cSCC, which comprise 20% of all
non-melanoma skin cancers, can be treated via ILP-TNF/Mel (Huis
In ‘t Veld et al, 2018). In fact, ILP-TNF/Mel can achieve a limb
salvage rate of 80% in such patients with a 2-year overall progres-
sion-free survival of 67%. Accordingly, cell lines derived from
patients with such malignancies (Hassan et al, 2019) are sensitive
to TNF/SM-induced cell death that is caspase-dependent (Figs 2L–N
and EV2L–N). Together, our observations indicate that SM sensitises
extremity malignancies to TNF-induced cell death, suggesting that it
might be beneficial to incorporate SM into current ILP-TNF/Mel,
standard-of-care treatment regimens.
RIPK1-induced cell death delays tumour growth and
prolongs survival
Next, we investigated whether SM enhances the efficacy of TNF/
Mel under in vivo settings. Our in vivo model of ILP with BN175
sarcoma mimics the clinical scenario, with an initial response to
ILP-TNF/Mel rapidly followed by local relapse (Smith et al, 2019).
Of note, this rat sarcoma model is highly aggressive, fast proliferat-
ing, and it is difficult to achieve a response. We used the SM Birina-
pant (Bir) for our in vivo experiments as this compound has
undergone clinical trial and is well tolerated (Condon et al, 2014;
Amaravadi et al, 2015). Importantly, Bir and SM-164 display the
same efficacy, killing BN175 cells to the same extent when
combined with TNF/Mel (compare Figs 1A and EV3A).
Tumour-bearing rats underwent ILP with the indicated therapeu-
tics and were then maintained for tumour growth and survival
endpoints (Figs 3A and B, and EV3B–E). While the delivery of SM
as a single therapy had minimal efficacy in comparison to untreated
controls, the combination of TNF/Mel with SM (red line), delivered
by ILP, significantly delayed tumour growth when compared to
TNF/Mel alone. The delay in tumour growth of animals treated with
TNF/Mel/SM translated into significantly prolonged survival when
compared to the standard-of-care TNF/Mel (Fig 3B, median 24.5 vs.
18 days, P = 0.0063, log-rank test). In clinical practice, the efficacy
of ILP is commonly evaluated by the percentage of non-viable cells
(dead cells, generally referred to as “necrosis”) in a resected speci-
men. To investigate the impact of TNF/Mel/SM, tumours were
collected 4 days post-ILP and subjected to histopathological analysis
(Fig 3C). These analyses indicated that TNF/Mel/SM significantly
increased tumour death compared to TNF/Mel alone (P = 0.0034,
unpaired t-test) (Fig 3C), in keeping with augmented therapy in this
therapeutic cohort.
Even though TNF/Mel/SM treatment significantly prolonged
survival in this highly aggressive model, tumour-bearing animals
still eventually reached the tumour growth endpoint (Fig EV3B–E).
To test whether this was due to the development of resistance to the
TNF/Mel/SM treatment or was caused by attaining a transient state
called “persistence” without mutation (Hangauer et al, 2017;
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Viswanathan et al, 2017), we isolated drug-tolerant tumour cells
from three rats (124, 133 and 136) that developed sarcomas post-
treatment. When these tumour cells were re-challenged, they were
as sensitive to TNF/Mel/SM treatment as the parental BN175 cells
(Fig 3D and E). This indicates that the surviving tumour cells are
persister cells and that drug tolerance was not due to clonal evolu-
tion of resistance mechanisms. This is in agreement with the notion
that ILP-mediated treatment is a one-off treatment protocol and so
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persistence more likely reflects lack of exposure rather than true
resistance.
The observation that surviving tumour cells are persister cells
has important implication for second-line treatment regimens
aimed at targeting residual disease. It indicates that the same
immunogenic cell death pathway can be re-engaged. To test this
principle, we activated Ripk1-induced cell death in the three
drug-tolerant tumour lines (124, 133 and 136) using Riboxxol.
Riboxxol is a synthetic TLR3 agonist that triggers Ripk1 activa-
tion (Lucifora et al, 2018; Schau et al, 2019) and that is well
tolerated when administered systemically or via intra-tumour
injections. We found that in combination with SM, Riboxxol
potently killed all three drug-tolerant tumour lines (Fig 3F). This
suggests that Riboxxol/SM may be used as second-line treatment
regimen for patients that develop locally progressive disease after
ILP (Smith et al, 2015).
An increase in locoregional toxicity was noted with TNF/Mel/SM
when compared with TNF/Mel (Fig EV3F). Locoregional toxicity is
typically graded using the Wieberdink scale (Wieberdink et al,
1982), with the majority of patients experiencing grade I–III reac-
tions (Smith et al, 2015). Minimal toxicity was noted when tumour-
bearing rats were treated with TNF/Mel, equating to grade I reac-
tions (Fig EV3F). In contrast, TNF/Mel/SM resulted in all animals
developing marked erythema and superficial desquamation, equat-
ing to grade III reactions. However, no functional compromise was
noted with these reactions, which gradually resolved over 2 weeks
following treatment (Fig EV3F). Such effects are seen following
standard-of-care ILP-TNF/Mel in patients and are effectively
managed with conservative measures in the majority of patients.
Together, our results suggest that the addition of SM to standard-of-
care ILP-TNF/Mel significantly improves animal survival. Our data
also suggest that second-line treatments with Riboxxol/SM might
further enhance efficacy.
RIPK1-induced cell death augments tumour immune infiltration
To determine whether Ripk1-induced cell death of BN175 sarcoma
cells is capable of mobilising the immune system, we profiled infil-
trating immune cell populations post-therapy. Tumours were
collected from rats at day 4 post-ILP (Fig 4A). Importantly, TNF/
Mel/SM treatment caused an increase in immune infiltration of
BN175 sarcoma, leading to elevated levels of T cells (Fig 4B) and
natural killer (NK) cells (Fig 4C). While ILP with TNF/Mel had a
negative effect on NK cell infiltration (Fig 4C), co-treatment with
SM significantly rescued NK activity (Figs 4D and EV4A). Moreover,
treatment with TNF/Mel/SM led to a recruitment of cytotoxic T cells
when compared to TNF/Mel treatment (Figs 4E and EV4B).
CD3+CD8+CD161 cytotoxic T cells also had considerably higher
Granzyme B expression upon TNF/Mel/SM treatment (Fig 4F).
Alongside these increases in immune effector cells, treatment
with TNF/Mel/SM resulted in a significant reduction of
CD3+CD4+Foxp3 T helper cells, with a corresponding increase in
CD3+CD4+Foxp3+ regulatory T cells (T-regs) (Fig 4G and H).
When compared to TNF/Mel, the addition of SM also led to
increased expression of the activation marker ICOS on T-reg cells
(Fig 4I). Together, these data suggest that the addition of SM to the
ILP standard-of-care TNF/Mel treatment activates the immune
system to BN175 sarcoma, leading to activation of infiltrating T
cells. However, both cytotoxic and regulatory T-cell populations
appear to be activated.
We also intended to use immunocompromised rats (Fisher-
F344.Cg-Foxn1rnu and hooded pigmented Hsd:RH-Foxn1rnu) to eval-
uate whether TNF/Mel/SM promotes immunogenic cell death.
However, we found that the vascular anatomy in the legs of the
Fisher and hooded rats are not suitable for ILP micro-surgery. This
is because these rat strains lack collateral anastomosing circulation
that is necessary to sustain the viability of the limb (Fig EV4D).
Therefore, we were not able to use immune-compromised rat strains
to address the contribution of the immune system.
Combination therapy with SM and checkpoint inhibitors further
prolongs recurrence-free survival following ILP-mediated TNF/
Mel treatment
Next, we investigated whether combination therapy with immune
checkpoint inhibitors might further improve survival. As no thera-
peutic rat-specific anti-CTLA-4 antibodies are available, we first
tested the cross-reactivity of the murine-specific 9H10 CTLA-4 anti-
body clone using a flow cytometry assay (Fig EV5A). Recombinant
rat CTLA-4 protein was conjugated to flow cytometry beads and
then stained with an isotype control or the murine-specific 9H10
clone. Increased fluorescence was noted with the 9H10 clone when
compared with the isotype control, indicating that the
mouse-specific anti-CTLA-4 antibody indeed detects rat CTLA-4
◀ Figure 1. The addition of SM to TNF/Mel sensitises cells to RIPK1-dependent cell death.A Cell viability analysis using CellTiter-Glo of BN175 cells treated with the indicated agents for 24 and 48 h (n = 4 biological replicates). Cell viability values are
displayed as a percentage of the relative untreated control. DMSO (Unt), TNF (10 ng/ml), SM (100 ng/ml) and Mel (3.3 lM). SM represents SM-164. Error bars
represent SD and statistical analysis was performed with an unpaired t-test, ****P ≤ 0.0001. Exact P values are shown in Appendix Table S1.
B TNF-induced complex-II immunoprecipitation. BN175 cells were treated with the indicated agents for 8 h. FADD immunoprecipitation was performed followed by
Western blot analysis (n = 3 biological replicates, shown is a representative experiment). DMSO (Unt), zVAD (10 lM), TNF (10 ng/ml), SM (100 ng/ml) and Mel
(3.3 lM).
C Proximity ligation assay between Ripk1 and Casp-8 performed in BN175 cells upon treatment with the indicated agents for 8 h (n = 3 biological replicates, shown are
representative images). Scale bar represents 10 lm. DMSO (Unt), zVAD (10 lM), TNF (10 ng/ml), SM (100 ng/ml) and Mel (3.3 lM).
D DEVDase activity assay of BN175 cells treated with the indicated drugs for 6 h (n = 3 biological replicates). DMSO (Unt), TNF (10 ng/ml), SM (100 ng/ml) and Mel
(3.3 lM). Error bars represent SD, and statistical analysis was performed with an unpaired t-test, ****P ≤ 0.0001. Exact P values are shown in Appendix Table S1.
E Cell viability analysis using CellTiter-Glo of BN175 CRISPR/Cas9 Ripk1 and Casp-8 knockouts (KO) cells treated with the indicated agents for 18 and 48 h (n = 3
biological replicates). Cell viability values are displayed as a percentage of the relative untreated control. SM represents SM-164. Error bars represent SD, and a
one-way ANOVA was performed to compare the mean value of each treatment to the treated BN175 CRISPR/Cas9 control (Ctrl), ****P ≤ 0.0001. Exact P values are
shown in Appendix Table S1.
Source data are available online for this figure.
ª 2020 The Authors EMBO Molecular Medicine e10979 | 2020 5 of 17
Henry G Smith et al EMBO Molecular Medicine
A B
H
D E F
G
IP
: α
-
CA
SP
-8
In
pu
t
(kDa)
WB:
α-RIPK1 RIPK175
CASP-8WB:
α-CASP-8
50
75
WB:
α-HSP90
110
WB:
α-RIPK1 RIPK1
HSP90
TNF: - + + -
- + - +SM:
CASP-850
1 2 3 4
WB:
α-CASP-8
Complex-II pulldown 8 hrs
HT1080 - Fibrosarcoma
****P < 0.0001
0
10
20
30
%
 
PI
-
po
sit
ive
 ce
lls
 (D
e
a
d 
Ce
lls
)
40
50
SW-872 - Liposarcoma
In
pu
t
(kDa)
TNF: - + - +
- - + +SM:
1 2 3 4
A375 - Melanoma
Complex-II pulldown 6 hrs
RIPK1
CASP-8
RIPK1
HSP90
CASP-8
WB:
α-RIPK1
WB:
α-CASP-8
WB:
α-HSP90
WB:
α-RIPK1
WB:
α-CASP-8
75
50
75
110
50
IP
: α
-
CA
SP
-8
0
20
40
60
A375 - Melanoma
****P < 0.0001
%
 
PI
-
po
sit
ive
 ce
lls
 (D
e
a
d  
Ce
lls
)
MeWo - Melanoma DO4 - Melanoma
****P < 0.0001
****P < 0.0001
****P < 0.0001
****P < 0.0001
I
siCTRL siRIPK1 siCASP-8
0
20
40
60
80
100
Ce
llT
ite
r-G
lo
 a
ss
ay
(%
 V
iab
ilit
y)
A375 - Melanoma
Un
t Un
t 
Un
t 
TN
F/S
M
TN
F/S
M
TN
F/S
M
********
siCTRL siRIPK1 siCASP-8
Un
t Un
t 
Un
t 
TN
F/S
M
TN
F/S
M
TN
F/S
M
0
20
40
60
%
 
PI
-
po
sit
ive
 ce
lls
 (D
e
a
d 
Ce
lls
)
80
100
********
C
HT1080 - Fibrosarcoma HT1080 - Fibrosarcoma
Un
t SM
TN
F/S
M
TN
F/S
M/
zV
AD
%
 
PI
-p
os
itiv
e 
ce
lls
 (D
e
a
d 
Ce
lls
)
0
20
40
60
HS-ES-2R - Epithelioid Sarcoma
***P < 0.001
Un
t SM
TN
F/S
M
30
40
50
60
70
20
10%
 
PI
-
po
sit
ive
 ce
lls
 (D
e
a
d 
Ce
lls
)
HS-SY-II - Synovial Sarcoma
***P < 0.001
K
J
L
Un
t 
TN
F SM
zV
AD
TN
F/S
M
TN
F/S
M/
zV
AD
0
20
40
60
%
 
PI
-
po
sit
ive
 ce
lls
 (D
e
a
d 
Ce
lls
)
Un
t 
TN
F SM
zV
AD
TN
F/S
M
TN
F/S
M/
zV
AD
20
40
80
60
%
 P
I-p
os
itiv
e 
ce
lls
 (D
ea
d 
Ce
lls
)
0 0
20
40
60
80
100
%
 
PI
-
po
sit
ive
 ce
lls
 (D
e
a
d 
Ce
lls
)
Un
t 
TN
F SM
zV
AD
TN
F/S
M
TN
F/S
M/
zV
AD
0 0
25
50
75
100
125
150
De
ad
 c
el
ls
/m
m
Un
t SM
TN
F/S
M
TN
F/S
M/
zV
AD
2
****P < 0.0001
****P < 0.0001
MET1 - Patient Derived Cutaneous 
Squamous Cell Carcinoma M
Un
t SM
TN
F/S
M
TN
F/S
M/
zV
AD
0
20
40
60
80
100
120
140
De
ad
 c
el
ls
/m
m
2
****P < 0.0001
****P < 0.0001
MET2 - Patient Derived Cutaneous 
Squamous Cell Carcinoma N
Un
t SM
TN
F/S
M
TN
F/S
M/
zV
AD
0
20
40
60
80
De
ad
 c
el
ls
/m
m
2
****P < 0.0001
***P < 0.001
IC8 - Patient Derived Cutaneous 
Squamous Cell Carcinoma
Un
t 
TN
F SM
zV
AD
TN
F/S
M
TN
F/S
M/
zV
AD
Un
t 
TN
F SM
zV
AD
TN
F/S
M
TN
F/S
M/
zV
AD
Figure 2.
6 of 17 EMBO Molecular Medicine e10979 | 2020 ª 2020 The Authors
EMBO Molecular Medicine Henry G Smith et al
(Fig EV5A). The suitability of the rodent-specific anti-PD-1 antibody
(J43) in rats has been demonstrated previously (Smith et al, 2019).
Next, we combined the ILP standard-of-care treatment (TNF/
Mel) with SM and checkpoint inhibitors. Tumours were engrafted,
and the ILP procedure performed at day 6 after implantation.
Following the ILP procedure, tumour-bearing animals received an
intraperitoneal injection of anti-CTLA-4 antibody, anti-PD-1 anti-
body or an isotype control, at day 8, 10 and 12 post-implantation.
No further treatment was given, and animals were maintained for
tumour growth and survival endpoints. Interestingly, the addition of
checkpoint inhibitors was beneficial as they further prolonged
survival when combined with ILP-TNF/Mel/SM (Figs 5A and B,
and EV5B–G). This clearly demonstrates that the inclusion of SM
and checkpoint inhibitors to the current standard-of-care treatment
is highly favourable.
Addition of anti-CTLA-4 antibodies to ILP-TNF/Mel/SM led to a
significant increase of T helper cells and also caused a reduction of
intra-tumoural CD3+CD4+Foxp3+ regulatory T cells (Fig 5C and
D). On the other hand, treatment with anti-PD-1 antibodies caused a
significant increase in active NK cells (Fig 5E). No alteration in the
recruitment or activity status of cytotoxic T cells was noted
(Fig EV5H–J).
SM improves anti-tumour immunity of
standard-of-care treatment
In clinical practice, ILP is often used as a neoadjuvant therapy
prior to surgery. To replicate this scenario, we developed a
neoadjuvant ILP model with the aim of securing local disease
control (Fig 6A). This methodology also allowed us to evaluate
whether the different treatment combinations have differential
effects on the initiation of long-term anti-tumour immunity.
Animals underwent the ILP procedure 6 days after tumour
implantation, followed by surgical resection at day 10. Animals
were then observed up to 60 days after implantation for signs of
local disease recurrence. All tumour resections were macroscopi-
cally complete, with no incidence of tumour spillage. We noticed
a significant therapeutic improvement when SM was combined
with the current standard-of-care treatment (TNF/Mel), with
TNF/Mel/SM being significantly more effective than TNF/Mel in
shrinking tumour volume at the time of surgery (P ≤ 0.0001,
unpaired t-test with Welch’s correction) (Fig 6B). ILP-TNF/Mel/
SM was also more potent than the standard-of-care treatment in
limiting local recurrence, with local recurrence occurring in only
one out of six animals (16.7%) treated with ILP-TNF/Mel/SM. In
contrast, three out of six ILP-TNF/Mel-treated animals (50%) suf-
fered local recurrence (Fig 6C). We also investigated the impact
of checkpoint inhibitors in this setting. We noticed no further
improvement in local disease control in comparison to ILP-TNF/
Mel/SM alone.
Next, we investigated if ILP-TNF/Mel/SM had any impact on
long-lasting anti-tumour immunity. To this end, we re-challenged
animals whose tumour was resected at day 10, and which
remained tumour-free till day 60 (see scheme Fig 6A). Tumours
were implanted in the contralateral limb of tumour-free animals,
and animals observed for tumour growth. In clinical practice,
ILP is generally considered to have minimal impact on anti-
tumour immunity and few if any abscopal effects. Consistent
with the clinical finding, ILP-TNF/Mel had little effect on tumour
growth at the challenge site in comparison to an untreated
control (median 14 vs. 12 days, P = 0.3173, log-rank test)
(Figs 6D and E, and EV6A and B). In contrast, animals that
were co-treated with SM (ILP-TNF/Mel/SM) were protected from
tumour challenge to a greater degree, displaying prolonged
◀ Figure 2. SM sensitise a panel of human extremity malignancies cell lines to TNF-induced cell death.A TNF-induced complex-II immunoprecipitation. HT1080 cells were treated with the indicated agents for 8 h. CASP-8 immunoprecipitation was performed followed
by Western blot analysis (n = 3 biological replicates, shown is a representative experiment). DMSO (Unt), zVAD (10 lM), TNF (10 ng/ml) and SM (100 ng/ml).
B Cell death analysis measured by Celigo of PI-positive HT1080 cells, and cells were treated with the indicated agents for 24 h. (n = 3 biological replicates). DMSO
(Unt), zVAD (10 lM), TNF (10 ng/ml) and SM (100 ng/ml). SM represents SM-164. Error bars represent SD, and an unpaired t-test was performed, ****P ≤ 0.0001.
Exact P values are shown in Appendix Table S1.
C Cell death analysis by Celigo of PI-positive HT1080 cells treated with the indicated agents for 72 h following siCTRL, siRIPK1 or siCASP-8 knockdown for 48 h (n = 3
biological replicates). DMSO (Unt), TNF (10 ng/ml) and SM (100 ng/ml). SM represents SM-164. Error bars represent SD, and a one-way ANOVA was performed,
****P ≤ 0.0001. Exact P values are shown in Appendix Table S1.
D TNF-induced complex-II immunoprecipitation. A375 cells were treated with the indicated agents for 6 h. Caspase-8 immunoprecipitation was performed followed
by Western blot analysis. DMSO (Unt), zVAD (10 lM), TNF (10 ng/ml) and SM (100 ng/ml) (n = 3 biological replicates, shown is a representative experiment).
E Cell death analysis by Celigo of PI-positive A375 treated with the indicated agents for 12 h. DMSO (Unt), zVAD (10 lM), TNF (10 ng/ml) and SM (100 ng/ml). SM
represents SM-164. Error bars represent SD. Displayed are representative results from n = 3, and statistical analysis was performed with an unpaired t-test,
****P ≤ 0.0001. Exact P values are shown in Appendix Table S1.
F Cell viability analysis using CellTiter-Glo of A375 cells treated with the indicated drugs for 24 h following siCTRL, siRIPK1 or siCASP-8 knockdown for 48 h (n = 3
biological replicates). Cell viability values are displayed as a percentage of the relative untreated control. DMSO (Unt), TNF (10 ng/ml) and SM (100 ng/ml). SM
represents SM-164. Error bars represent SD, and a one-way ANOVA was performed to compare the mean value of each treatment to the treated A375 siCTRL,
****P ≤ 0.0001. Exact P values are shown in Appendix Table S1.
G–I Cell death analysis by Celigo of PI-positive MeWo (G), DO4 (H) or SW-872 (I) cells. Cells were treated with the indicated agents for 24 h (MeWO and SW-872) or
12 h (DO4). DMSO (Unt), zVAD (10 lM), TNF (10 ng/ml) and SM (100 ng/ml) SM represents SM-164. Error bars represent SD. Displayed are representative results
from n = 3, and statistical analysis was performed with an unpaired t-test, ****P ≤ 0.0001. Exact P values are shown in Appendix Table S1.
J, K Cell death analysis by Celigo of PI-positive HS-ES-2R (J) and HS-SY-II (K) cells. Cells were treated with the indicated agents for 48 h (HS-ES-2R) or 24 h (HS-SY-II).
DMSO (Unt), zVAD (10 lM), TNF (100 ng/ml) and SM (100 ng/ml) SM represents SM-164. Error bars represent SD. Displayed are representative results from n = 3,
and statistical analysis was performed with an unpaired t-test, ***P ≤ 0.001. Exact P values are shown in Appendix Table S1.
L–N Cell Death analysis by IncuCyte Zoom of CellTox Green-positive MET1 (L), MET2 (M) and IC8 (N) cells. Cells were treated with the indicated agents for 40 h. DMSO
(Unt), zVAD (10 lM), TNF (10 ng/ml) and SM (100 ng/ml) SM represents SM-164. Error bars represent SD. Displayed are representative results from n = 6, and
statistical analysis was performed with a one-way ANOVA, ***P ≤ 0.001, ****P ≤ 0.0001. Exact P values are shown in Appendix Table S1.
Source data are available online for this figure.
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survival even in a highly aggressive model (median 20 vs.
14 days, P = 0.0259, log-rank test) (Fig 6D and E). Our data are
consistent with the notion that treatment with ILP-TNF/Mel/SM
drives anti-tumour immunity and is significantly more effective
than the current standard-of-care treatment. Therefore, our find-
ings warrant a clinical trial to assess the survival benefit of
RIPK1-induced cell death in patients with advanced disease at
limb extremities.
Discussion
The pathways that initiate and execute immunogenic cell death are
complex, genetically encoded and subject to significant regulation.
Here, we report the first clinical application of an in vivo treatment
protocol that directly engages RIPK1-mediated immunogenic cell
death. Using a rat model of aggressive extremity sarcoma, we
demonstrate that TNF-mediated cell death significantly improves
local disease control, increases activation of infiltrating CD8+ T cells
and NK cells, and enhances the survival benefit of immune check-
point blockade. Therefore, our findings warrant clinical evaluation
of the survival benefit of TNF/Mel/SM in combination with
checkpoint inhibitors in patients with advanced disease at limb
extremities.
Regional chemotherapy by isolated limb perfusion (ILP) was
introduced as a therapy to treat advanced extremity malignancies
either as a standalone treatment or as a neoadjuvant treatment to
downsize a malignancy and facilitate function-preserving surgery.
Although combination treatment with TNF and melphalan-based
ILP can provide initial good responses, the effects are generally
short-lived with the disease progressing with 12 months (Eggermont
et al, 1996, 2003; Deroose et al, 2012). While TNF is used for its
vasodilating properties during ILP, its anticancer potential has never
been exploited. SM compounds that antagonise cIAP1/2 have
received attention as potential cancer therapeutics because cIAP1/2
are overexpressed in many cancer types and their elimination from
cancer cells often induces TNF-driven apoptosis (Vince et al, 2007;
Bai et al, 2014; Fulda, 2015).
Several lines of evidence indicate that combining SM with the
current standard-of-care ILP-TNF/Mel regimen is more efficacious
in treating extremity sarcomas than ILP-TNF/Mel alone. First,
treatment with SM enhances tumour kill in response to TNF/Mel
in vitro as well as in vivo. Intriguingly, the area of necrotic
(dead material) tumour mass post-ILP treatment is a recognised
prognostic marker for local recurrence (Deroose et al, 2011a).
Hence, the degree of dead material (“necrotic area”) is used to
determine whether a patient will have to undergo adjuvant
radiotherapy. In line with this clinical assessment, we found that
the enhanced necrotic area of ILP-TNF/Mel/SM-treated tumours
correlated with improved long-term local disease control, when
compared to standard-of-care ILP-TNF/Mel (in our neoadjuvant
protocol). Importantly, the addition of SM to ILP-TNF/Mel may
not only prolong local disease control but also reduce the
requirement for radiotherapy, which is of particular value given
that ILP is often performed in relatively younger patients.
Second, SM compounds unleash the cytotoxic potential of TNF,
driving TNF signalling in favour of RIPK1- and CASP-8-mediated
cell death. This death pathway runs in parallel to the one trig-
gered by Mel and hence adds to the complexity of cell death
signalling. Third, TNF/Mel/SM-induced cell death appears to be
more immunogenic, as cancer cells that die in this way more
efficiently induce anti-tumour immunity. This observation is
supported by recent studies demonstrating that activation of
innate immune pathways within dying cells, such as activation
of NF-jB, represents an earlier immunological event that regu-
lates the outcome of T-cell priming (Yatim et al, 2015, 2017).
This is because TNF can trigger cell death as well as NF-jB-
dependent production and release of “danger signals” from dying
cells that attract and stimulate immune cells. Thus, enhancing
TNF killing by inhibiting IAPs is likely to drive an immunologi-
cal response. Consistent with this notion, we found that the
addition of SM to the standard-of-care treatment ILP-TNF/Mel
leads to an increase in the number of activated CD8+ T cells
and NK cells. However, this was accompanied by an increase in
the population of CD3+CD4+Foxp3+ T-reg cells with immuno-
suppressive activities. Consistent with the notion that immune
suppressive activities are present, we found that co-treatment
with anti-CTLA-4 or anti-PD-1 antibodies significantly enhanced
the survival benefit of ILP-TNF/Mel/SM. Accordingly, checkpoint
blockade caused T-reg depletion or boosted NK cell activation.
◀ Figure 3. RIPK1-induced cell death delays tumour growth and prolongs survival.A Measurements of tumour volume of the respective cohorts (n = 6 animals per cohort). SM represents Birinapant. Error bars represent SD. Statistical analysis was
performed with an unpaired t-test, *P ≤ 0.05, ***P ≤ 0.001. Exact P values are shown in Appendix Table S1.
B The addition of SM to the standard-of-care treatment ILP-TNF/Mel significantly prolonged survival compared to either modality alone (n = 6 rats per cohort).
Statistical analysis was performed with a log-rank test, **P ≤ 0.01. Exact P values are shown in Appendix Table S1.
C Representative images of area of dead cells and respective quantification from tumours resected from animals 10 days post ILP-TNF/Mel or ILP-TNF/Mel/SM (n = 6
animals per cohort). SM represents Birinapant. Median TNF/Mel is 0.4472 and TNF/Mel/SM is 1.154. TNF/Mel 25th percentile limit 0.02887 and 75th percentile limit
0.7627. TNF/Mel/SM 25th percentile limit 1.136 and 75th percentile limit 1.67. TNF/Mel Min error bar 0.2389 and Max 0.7687. TNF/SM/Mel Min error bar 1.12 and Max
1.813. Error bars represent SD. Statistical analysis was performed with an unpaired t-test, **P ≤ 0.01. Exact P values are shown in Appendix Table S1.
D DEVDase activity assay of parental BN175 cells and drug-tolerant tumour cell lines isolated from ILP-TNF/Mel/SM-treated animals (124, 133, 136), treated with the
indicated drugs for 6 h (n = 4 biological repeats). DMSO (Unt), Mel (3.3 lM), TNF (10 ng/ml) and SM (100 ng/ml).
E Cell viability analysis using CellTiter-Glo of BN175 parental and 124, 133 and 136 cells treated with the indicated drugs for 24 h (n = 3 biological repeats). DMSO
(Unt), Mel (3.3 lM), TNF (10 ng/ml) and SM (100 ng/ml). SM represents SM-164. Error bars represent SD. Statistical analysis was performed with a one-way ANOVA,
ns = not significant. Exact P values are shown in Appendix Table S1.
F Cell viability analysis using CellTiter-Glo of BN175 CRISPR/Cas9 Ripk1 and Casp-8 KO cells treated with the indicated agents for 24 h (n = 3 biological replicates). Cell
viability values are displayed as a percentage of the relative untreated control. DMSO (Unt), SM (100 ng/ml) and Riboxxol (1 lg/ml). SM represents SM-164. Error bars
represent SD and a one-way ANOVA was performed to compare the mean value of each treatment to the treated BN175 CRISPR/Cas9 control (Ctrl), ****P ≤ 0.0001.
Exact P values are shown in Appendix Table S1.
Source data are available online for this figure.
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The immune cell types characterised in this study represent
just a fraction of the diverse populations that comprise the
tumour microenvironment, with other cell types such as macro-
phages, fibroblasts and B cells, as well as stromal components,
increasingly recognised as crucial players in tumour response and
resistance to therapy (Chen & Mellman, 2017). While it would
have been ideal to investigate the contributions of such cells
types in this model, the availability of high quality rat-specific
reagents was a limiting factor. However, clinical translation of
this combination therapy would provide the opportunity for a
more comprehensive evaluation of the effects of ILP-TNF/Mel/SM
on the tumour microenvironment.
Further, our data demonstrate that the addition of SM to the
standard-of-care ILP treatment TNF/Mel can promote abscopal
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Figure 4. RIPK1-induced cell death augments tumour immune infiltration.
A–I Flow cytometry analysis of tumours collected on Day 10 following treatment (n = 3 animals per group). (A) Schematic representation of the experimental setup. ILP
with TNF/Mel/SM significantly increased infiltration by CD3+ lymphocytes (B) and CD3CD161+ NK cells (C). While ILP treatment with TNF/Mel significantly reduced
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Source data are available online for this figure.
10 of 17 EMBO Molecular Medicine e10979 | 2020 ª 2020 The Authors
EMBO Molecular Medicine Henry G Smith et al
immunity. Accordingly, tumour growth upon re-challenge of long-
term survivors following neoadjuvant ILP-TNF/Mel/SM was
significantly delayed in comparison to survivors of the ILP-TNF/
Mel treatment arm (Fig 6E), indicating the induction of a degree
of systemic anti-tumour immunity. This is an important issue as
current treatment regimens can only treat the perfusion field and
have no significant impact on the dissemination of disease or
overall survival.
Even though TNF/Mel/SM treatment significantly prolonged
survival in this highly aggressive model, tumour-bearing animals
still eventually reached the tumour growth endpoint. This could be
due to the constraint of the ILP procedure, which only allows the
chemotherapy to be administered once, and this could limit the
degree of anti-tumour immunity established. Accordingly, isolated
drug-tolerant tumour cells, isolated from rats that developed sarco-
mas post-treatment, remained as sensitive to the treatment as
parental cells, demonstrating that “resistance” to the TNF/Mel/SM
treatment was caused by attaining a transient state called “persis-
tence” without mutation (Hangauer et al, 2017; Viswanathan et al,
2017). This has important ramifications, as it suggests that a similar
line treatment regimen, such as SM/Riboxxol, might be used for
patients that develop locally progressive disease after ILP (Smith
et al, 2015).
The combination of SM with ILP-TNF/Mel has the potential
for direct clinical translation in both palliative and neoadjuvant
protocols. While our in vivo studies were limited to a single
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C–E Tumours were collected 4 days after the ILP procedure and analysed by flow cytometry (n = 3 per cohort). The addition of anti-CTLA-4 antibodies
led to a significant increase in CD4+Foxp3 helper T cells (C) accompanied by a depletion of CD4+Foxp3+ regulatory T cells (D). The addition of
anti-PD-1 antibodies led to an increase in Granzyme B (GzmB) expression on NK cells (E). SM represents Birinapant. Error bars represent SD and a
one-way ANOVA was performed *P ≤ 0.05. Abbreviations: positive (+ve), negative (ve), Granzyme B (GzmB). Exact P values are shown in
Appendix Table S1.
Source data are available online for this figure.
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sarcoma model, our in vitro data indicate that this treatment
combination has the potential to improve response to ILP-TNF/
Mel in a range of pathologies and histological subtypes. Further,
while it may augment the initial response to therapy in extremity
malignancies, it may also make them more susceptible to subse-
quent immunotherapies.
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Figure 6. SM improves anti-tumour immunity of standard-of-care treatment.
A Schematic representation of the experimental setup.
B Tumour volumes at the time of surgery following ILP-TNF/Mel or ILP-TNF/Mel/SM (n = 6 animals per cohort). SM represents Birinapant. Error bars represent SD.
Statistical analysis was performed with an unpaired t-test, ****P ≤ 0.0001. Exact P values are shown in Appendix Table S1.
C Individual growth curves following surgery indicated improved control following ILP-TNF/Mel/SM (n = 6 animals per cohort).
D Tumour volume on re-challenge with BN175 sarcoma on contralateral limb of long-term survivors following ILP-TNF/Mel or ILP-TNF/Mel/SM (n = 3 animals per TNF/
Mel cohort and n = 5 per TNF/Mel/SM cohort). Unless otherwise stated, SM represents Birinapant. Error bars represent SD.
E ILP-TNF/Mel/SM significantly delayed growth leading to prolonged survival on re-challenge (n = 3 animals per TNF/Mel cohort and n = 5 per
TNF/Mel/SM cohort). SM represents Birinapant. Statistical analysis was performed with a log-rank test, *P ≤ 0.05. Exact P values are shown in
Appendix Table S1.
Source data are available online for this figure.
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Materials and Methods
Study design
Using an immune-competent, orthotopic and metastatic animal
model of ESTS, we assessed the therapeutic benefit of adding SM to
the locoregional delivery of ILP.
The ability of this combination therapy to control local and
systemic disease relapse was evaluated in both palliative and neoad-
juvant protocols. To elucidate the mechanism responsible for
enhanced therapy, we characterised effects of treatment on the
tumour microenvironment in our in vivo model using flow cytome-
try and immunohistochemistry. A single investigator performed all
the surgical procedures. Sample sizes were determined using a
power calculation based on detecting a 20% difference between
control and treated cohorts.
Reagents and antibodies
DISC lysis buffer (20 mM Tris–HCL pH7.5, 150 mM NaCl, 2 mM
EDTA, 1% Triton X-100, 10% Glycerol, H2O). The following
reagents were used: human and mouse TNF (Enzo), zVAD-FMK
(Apex Bio), SM-164 (gift from Shaomeng Wang), Ripk1i (GSK’963,
gift from GlaxoSmithKline plc.), doxycycline (DOX) (BD
Bioscience), Riboxxol (Riboxx Gmbh). The following antibodies
were used: a-RIPK1 (Cell Signaling; 3493), a-CYLD (Cell Signaling;
D1A10), a-SHARPIN (Proteintech), a-TRADD (BD Biosciences), a-
TNFR1 [H5] (Santa Cruz Biotechnology), a-HSP90 (Santa Cruz
Biotechnology), a-CASP-8—for Western blot (WB)—post-immune-
precipitation (IP) (MBL), a-CASP-8—for IP [C-20] (Santa Cruz
Biotechnology), a-Casp-8 for rat (Cell Signalling; 9429), a- FADD for
IP and WB [M-19] (Santa Cruz Biotechnology), a-Ripk3 (Pro-
science; 2283). All antibodies were used at a 1:1,000 dilution.
Tissue culture
HT1080, A375, SW-872, MeWO, DO4, HS-ES-2R, HS-SY-II, HS-ES-
2M, HS-ES-I, SCC-9 and SCC-12 cell lines were obtained from ATCC.
BN175 cells were a kind gift from Professor A Eggermont. HT1080,
A375, SW-872, MeWO, DO4, HS-ES-2R, HS-SY-II, HS-ES-2M, HS-
ES-I, SCC-9, SCC-12, BN175 and primary mouse dermal fibroblasts
(MDF) cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM). Culture media were supplemented with 10% foetal bovine
serum (Gibco), penicillin and streptomycin. HT1080 cells were
stably transduced with Dox-inducible BCL2 or RFP and cultured in
Dulbecco’s modified Eagle’s medium (DMEM). Culture media were
supplemented with 10% foetal bovine serum (Gibco), penicillin and
streptomycin and Dox (100 ng/ml). All cells were cultured under
10% CO2. Ethical approval and written informed consent was
obtained from all subjects prior to isolation of primary keratinocytes
from cSCC tumours as published previously (Purdie et al, 2011;
Watt et al, 2011). Experiments conformed to the principles set out
in the WMA Declaration of Helsinki and the Department of Health
and Human Services Belmont Report. SCCMET1, SCCMET2 and
SCCMET4 were isolated from the same patient from the primary,
recurrence and metastatic tumour sites, respectively (Proby et al,
2000). SCCIC8 was isolated from an immune-competent patient and
SCCT1 from a transplant patient.
IncuCyte cell death assay
Primary keratinocytes were seeded at 1 × 103 cells/well in a 96-well
plate. Cells were treated with the indicated treatments, and 0.04 ll
of CellToxTM Green (Promega, G8731) express reagent was added to
each well at the start of the assay. Cells were imaged every 4 h
using the IncuCyte ZOOM live cell imaging system (Essen
Bioscience, Inc.) to record percentage confluence and number of
dead cells (green object count/mm2) per well.
Cell death (Celigo) and viability (CellTiter-Glo)
For CeligoS assays, 8 × 103 cells were seeded in 96-well plates, and
24 h later, cells were treated as indicated for the indicated times.
Hoechst (0.5 lg/ml) and PI (1 lg/ml) were added, and the percent-
age of dead cells was measured using the CeligoS image cytometer
(Nexcelom Bioscience). Cell viability was determined using Cell-
Titer-Glo reagent (Promega). Luminescence values were normalised
to the median of the per-plate DMSO vehicle only control well.
Caspase activity assays (DEVDase)
DEVDase assay was performed as previously described (Feltham
et al, 2018). In brief, cells were plated in 96-well plates and retro
siRNA transfection was performed for 40 h. After treatment,
medium was removed and 1% DISC lysis buffer was added to each
well. Plates were placed at 80°C to aid cell lysis. Plates were
thawed at room temperature for 15 min, after which DEVDase assay
mix was added to each well (NB: cell lysates were not cleared). The
plates were wrapped in foil, and the reaction was incubated at room
temperature for up to 24 h. DEVDase activity was read at 380 nM
excitation/460 nM emission.
Complex-I/II purification
Complex-I/II purification was essentially performed as previously
described (Feltham et al, 2018). In brief, cells were seeded in 15 cm
dishes and treated as indicated using pre-warmed media containing
3xFLAG-hTNF (0.8 lg/ml). After stimulation, media was removed
and plates were washed with ice cold PBS to stop stimulation and
frozen at 80°C. Plates were thawed, and cells were lysed in DISC
lysis buffer supplemented with protease inhibitors and PR619
(10 lM). Cell lysates were rotated at 4°C for 20 min then clarified at
4°C at 16,873 g for 10 min. 20 ll of anti-FLAG M2 beads (SIGMA)
were rotated with cleared protein lysates overnight at 4°C. 0 h
sample: 0.8 lg/ml of FLAG-TNF was added post-lysis. 4× washes in
DISC buffer with PR619 (10 lM) were performed, and samples
eluted by boiling in 50 ll 1× SDS loading dye. For complex-II purifi-
cation, cells were seeded in 10 cm dishes and treated as indicated in
figure legends. Cells were lysed on ice as above. Cell lysates were
rotated at 4°C for 20 min and then clarified at 4°C at 14,000 rpm for
10 min. 20 ll of protein G sepharose (SIGMA) with CASP-8 (C20)
antibody (Santa Cruz Biotechnology) (for Human) or FADD antibody
(Santa Cruz Biotechnology) (for rat) (1.5 lg antibody/mg protein
lysate) were rotated with cleared protein lysates overnight at 4°C. 4×
washes in wash buffer (50 mM Tris pH 7.5, 150 mM NaCl, 0.1%
Triton X-100, and 5% glycerol) were performed, and samples eluted
by boiling in 50 ll 1× SDS loading dye.
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Immunoblotting
Proteins lysates were quantified before separating samples by SDS–
PAGE using NuPAGE Novex 4–12% Bis-Tris 1.0 mm 12 well precast
protein gels (Invitrogen) in MES buffer.
Proximity ligation assay
PLA was performed as described previously (Orme et al, 2016;
Liccardi et al, 2018) using the Duolink Detection Kit (SIGMA)
following manufacturer’s instructions. Cells were examined with a
confocal microscope (objective × 40, Zeiss LSM 710). Briefly,
1 × 105 cells were plated on a 13 mm glass coverslip (VWR). The
following day, cells were treated with the indicated agents and fixed
in 4% PFA (paraformaldehyde) for 10 min. Cells were perme-
abilised in 1 × PBS, 0.5% Triton X 100 (Sigma) for 10 min and
blocked for 1 h in 1 × PBS, 5% BSA. The required primary antibod-
ies were then added overnight at 4°C. Proximity ligation was then
performed according to manufacturer’s instructions.
Generation of CRISPR cell lines
Guide RNAs targeting rat Ripk1 and Casp-8 were designed using
http://crispor.tefor.net. All guides were cloned into a lentiviral
vector-lentiCRISPR as previously described (McComb et al, 2016).
Two weeks after infection, cells were FACS sorted and used for
further assays. Guide sequences are as follows: Ripk1 guide 1—
CGATCGAGTGGTGAAGCTAC, Ripk1 guide 2—TGTGAAAGTCAC
GGTCAACG, Casp-8 guide 1—TACGATATTGCTGAACGTCT and
Casp-8 guide 2—GCAGATCCCGCCGACTGATA.
Therapeutic agents
Melphalan (Alkeran) was purchased from Laboratories Genopharm,
France. Recombinant hTNF was purchased from First Link Ltd
(Birmingham, UK). Birinapant was purchased from LC laboratories,
USA. Anti-CTLA antibody (clone 9H10) was purchased from 2BSci-
entific (Upper Heyford, UK).
In vitro validation of anti-CTLA-4 and anti-PD-1 antibody
cross-reactivity
Recombinant rat CTLA-4 protein was purchased from Sino Biologi-
cal (Wayne, PA, USA). After reconstitution, the recombinant protein
was conjugated to flow cytometry beads using the Functional Bead
Conjugation kit from Becton Dickinson (Wokingham, UK). Samples
were stained with the 9H10 anti-CTLA-4 antibody and the relevant
isotype control then with an Alexa Fluor 488 fluorescent secondary
antibody (Thermo Fisher Scientific, Hemel Hempstead, UK) and
assessed using flow cytometry. Recombinant rat PD-1 protein was
purchased from Sino Biological (Wyne, PA, USA), and cross-reac-
tivity has been previously validated (Smith et al, 2019).
In vivo studies
Inbred, male Brown Norway rats weighing between 225–275 g
were obtained from Envigo (Huntingdon, UK) (8/9 weeks old) and
housed on a 12-h light/dark cycle with unrestricted access to food
and water at all times. Tumours were established by injecting
1 × 107 BN175 cells subcutaneously into the left biceps femoris
muscle. Treatment was started 6 days after tumour implantation.
ILP was performed as previously described (Pencavel et al, 2015;
Smith et al, 2019) with 50 lg TNF and 100 lg Mel. In brief, a
hyperthermic perfusion with a target temperature of 40°C was
performed via a perfusion circuit established using the femoral
vessels and a desktop perfusion pump. For the relevant cohorts,
SM (Birinapant) was added to the perfusion circuit at a dose of
1.25 mg (approximately 5 mg/kg). Perfusion was performed for
10 min and washout for 2 min. Where applicable, anti-CTLA-4 or
anti-PD-1 antibodies were delivered by intraperitoneal injection at
doses of 500 and 200 mg, respectively, in three repeated doses at
48 h intervals. The control groups underwent a sham ILP proce-
dure to control for the impact of surgical intervention in these
experiments. Where applicable, tumour resections were performed
using a standardised compartmentectomy technique, whereby the
tumour was removed en-bloc within the biceps femoris muscle
(Smith et al, 2019). All tumours were resected with macroscopi-
cally clear margins (R1), and no evidence of tumour spillage was
noted. R0 margins were not assessed due to the concern that a
1 mm margin in animal model would not have the same relevance
as in the clinical context. For the re-challenge experiment in Fig 6,
tumours were implanted in the opposite leg. Due to the isolated
nature of ILP, this provided a remote site from the initial therapy
in which to evaluate the abscopal effect. An Institutional Animal
Care and Use Committee (IACUC) approved the in vivo experi-
ments. The dosing of these compounds was determined in previ-
ous studies (Pencavel et al, 2015; Wilkinson et al, 2016; Smith
et al, 2019). The 100 lg dose of Mel equates to a clinically rele-
vant dose of 50 mg. The dosage for SMAC mimetics, and in partic-
ular Birinapant, has previously been established for mouse as
10 mg/kg (Lalaoui et al, 2016). By applying the FDA guidelines for
dose conversion between species, this equates to 5 mg/kg for rats
(Nair & Jacob, 2016), which is what we used in our in vivo
ILP model.
Flow cytometry
Tumours were stained with the following rat-specific conjugated
antibodies: CD3-APC (1 lg/100 ll), CD4-FITC (0.25 lg/100 ll),
CD8-PerCP (0.25 lg/100 ll), CD161-PE (0.5 lg/100 ll), ICOS-
PECy7 (0.5 lg/100 ll), Granzyme B-Pacific Blue (0.5 lg/100 ll)
(BioLegend, San Diego, CA, USA); Foxp3-Alexa700 (0.25
lg/100 ll), Viability-APC Cy7 (1 ll/ml) (Thermo Fisher Scientific).
To determine the total numbers of NK and CD8+ CTLs within the
tumours, counting beads were added to each sample to allow the
proportion of each sample analysed to be calculated. This allowed a
multiplication factor to be calculated so that the total immune infil-
trate of the tumours could be estimated. This was then divided by
tumour weight.
Immunohistochemistry
Formalin-fixed paraffin-embedded (FFPE) sections were analysed
haematoxylin and eosin using standard protocols. The Nano-
zoomer-XR platform (Hamamatsu Photonics, Welwyn Garden City,
UK) was used to obtain digital images of stained slides.
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Statistical analysis
All statistical analyses were conducted using GraphPad Prism,
version 7.0 (San Diego, USA). Grouped data are presented as
means  SEM unless otherwise stated. Differences between multi-
ple groups were assessed using one- or two-way ANOVA with post
hoc analysis using Bonferroni’s correction. Differences between two
groups were assessed using a two-tailed unpaired t-test. Survival
outcomes were compared using the Kaplan–Meier method and the
log-rank test. Significance was determined at P < 0.05.
Expanded View for this article is available online.
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